Stable isotope metabolomics of pulmonary artery smooth muscle and endothelial cells in pulmonary hypertension and with TGF-beta treatment. by Hernandez-Saavedra, Daniel et al.
UCSF
UC San Francisco Previously Published Works
Title
Stable isotope metabolomics of pulmonary artery smooth muscle and endothelial cells in 
pulmonary hypertension and with TGF-beta treatment.
Permalink
https://escholarship.org/uc/item/5bw585hp
Journal
Scientific reports, 10(1)
ISSN
2045-2322
Authors
Hernandez-Saavedra, Daniel
Sanders, Linda
Freeman, Scott
et al.
Publication Date
2020-01-15
DOI
10.1038/s41598-019-57200-5
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1Scientific RepoRtS |          (2020) 10:413  | https://doi.org/10.1038/s41598-019-57200-5
www.nature.com/scientificreports
Stable isotope metabolomics of 
pulmonary artery smooth muscle 
and endothelial cells in pulmonary 
hypertension and with tGf-beta 
treatment
Daniel Hernandez-Saavedra1, Linda Sanders1, Scott freeman1, Julie A. Reisz2, 
Michael H. Lee1, claudia Mickael1, Rahul Kumar1,3, Biruk Kassa1,3, Sue Gu1, 
Angelo D’ Alessandro2, Kurt R. Stenmark  4, Rubin M. tuder1 & Brian B. Graham  1,3*
Altered metabolism in pulmonary artery smooth muscle cells (pASMcs) and endothelial cells (pAecs) 
contributes to the pathology of pulmonary hypertension (pH), but changes in substrate uptake and how 
substrates are utilized have not been fully characterized. We hypothesized stable isotope metabolomics 
would identify increased glucose, glutamine and fatty acid uptake and utilization in human pASMcs and 
pAecs from pH versus control specimens, and that tGf-β treatment would phenocopy these metabolic 
changes. We used 13c-labeled glucose, glutamine or a long-chain fatty acid mixture added to cell culture 
media, and mass spectrometry-based metabolomics to detect and quantify 13c-labeled metabolites. 
We found pH pASMcs had increased glucose uptake and utilization by glycolysis and the pentose 
shunt, but no changes in glutamine or fatty acid uptake or utilization. Diseased pAecs had increased 
proximate glycolysis pathway intermediates, less pentose shunt flux, increased anaplerosis from 
glutamine, and decreased fatty acid β-oxidation. tGf-β treatment increased glycolysis in pASMcs, but 
did not recapitulate the pAec disease phenotype. in tGf-β-treated pASMcs, glucose, glutamine and 
fatty acids all contributed carbons to the tcA cycle. in conclusion, pASMcs and pAecs collected from pH 
subjects have significant changes in metabolite uptake and utilization, partially recapitulated by TGF-β 
treatment.
Changes in cellular metabolism are increasingly recognized as a hallmark of pulmonary hypertension (PH) 
pathobiology1–4. Shifts in the uptake of metabolic substrates and how they are utilized downstream enables the 
disease phenotype of vascular cells in PH, including increased proliferation, apoptosis resistance, hypertrophy 
and vasoconstriction3. One critical metabolic shift observed in PH is an increase in glycolysis, which is thought 
to occur in resident vascular wall cells including pulmonary artery smooth muscle cells (PASMCs), endothelial 
cells (PAECs) and fibroblasts5–7. Increased glucose uptake can be demonstrated in vivo by increased uptake of the 
glucose analog 18F-fluorodeoxyglucose in the lung parenchyma of PH subjects6,8. The concept that glycolysis in 
PH is detrimental has led to investigation of the potential utility of dichloroacetate (DCA), which by blocking 
pyruvate dehydrogenase kinase causes increased glucose flux into the TCA cycle, and less glycolysis9. Glutamine 
uptake and metabolism by PAECs has also been shown to contribute to their disease phenotype10. However, 
comprehensive assessment of substrate uptake and how the substrates are utilized by pulmonary vascular cells in 
PH is lacking.
A potential driver of altered cellular metabolism is transforming growth factor β (TGF-β) signaling, which 
underlies many forms of heritable (through mutations in BMPR2 and other members of the TGF-β signaling 
superfamily) and idiopathic PAH, and PAH etiologies associated with other conditions such as autoimmune 
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disease and schistosomiasis11–13. TGF-β induces cellular phenotypes which require energy and metabolic sub-
strates, including proliferation, migration, contraction, and synthesis of cytokines and the extracellular matrix.
Here, we hypothesized that PASMCs and PAECs obtained from subjects with idiopathic pulmonary arte-
rial hypertension (IPAH) will have increased glycolysis, glutaminolysis, and fatty acid β-oxidation compared 
to cells from control subjects. We assessed the metabolism of primary cells derived from diseased and human 
donor lungs using stable isotope metabolomics, an approach that allows assessment of uptake and downstream 
utilization of labeled substrates. We found evidence of increased glycolysis and pentose shunt flux particularly 
in PASMCs. We also found evidence of increased glutamine metabolism in PAECs but not PASMCs. Diseased 
PAECs had evidence of less fatty acid metabolism. We were able to phenocopy aspects of the altered metabolic 
phenotype by treating the cells with TGF-β, most notably the glycolytic shift in PASMCs. Overall, our results indi-
cate PASMCs and PAECs in PH have quite different changes in their metabolic phenotype, and future therapeutic 
interventions targeting metabolism will likely benefit from cell compartment specificity.
Results
We obtained primary PASMCs and PAECs from explanted IPAH and unsuccessful donor control lung specimens 
collected by the Pulmonary Hypertension Breakthrough Initiative (PHBI), a multi-center consortium that col-
lects and distributes tissue specimens. We used N = 5 in each of the 4 categories (PASMCs and PAECs; diseased 
and control of each). The specimens had similar ages and sex distributions (Tables 1 and 2). Within these, we had 
N = 3 PASMCs and PAECs from the same diseased specimen, and N = 3 PASMCs and PAECs from the same 
control specimen. We added stable isotope-labeled metabolites–glucose, glutamine or a mixture of 4 long chain 
fatty acids–to the cell culture media, and following a 24 hour incubation, separated the supernatant from the cells 
and then performed metabolomics analysis on the samples.
increased glucose uptake and utilization by glycolysis and the pentose shunt in diseased 
pASMcs. We began by assessing the uptake and utilization of [1,2,3-13C3]glucose in diseased versus control 
PASMCs. Glucose labeled at carbons 1-3 allows the comparative assessment of glucose metabolism through glyc-
olysis versus the pentose shunt. When metabolized via glycolysis, 13C3 lactate is generated; in contrast, the activity 
of pentose shunt enzyme 6-phosphogluconate dehydrogenase evolves 13C1 as CO2, and subsequently glyceralde-
hyde 3-phosphate and other downstream metabolites re-entering the glycolytic pathway will be labeled as 13C214. 
We observed a higher 13C-labeled pyruvate and lactate content within diseased PASMCs compared to control 
PASMCs, although no differences at the level of more proximate metabolites (Fig. 1a): data consistent with the 
Control Subjects
PASMCs PAECs Age Sex
X 25 M
X 55 F
X X 24 M
X X 50 F
X X 36 F
X 55 F
X 49 M
Table 1. Age and sex of subjects for control PASMCs and PAECs.
Diseased Subjects
Cells Used
Age Sex BMPR2 mut
Pre Txplt RHC Medications
PASMCs PAECs
mPAP PVR1
PDE5inh/ ERA/Prost.2(mmHg) (WU)
X 57 F N 82 27.3 S/A/E
X 16 M N 63 20.5 T/-/E
X X 40 M N 73 16.8 S/A/T
X X 27 F c.76 + 5 G > A3 69 12.1 S/B/T
X X 53 M N 33 3.9 T/M/E
X 16 F N 95 N/A S/-/T
X 32 F N 47 16.4 -/B/E
Table 2. Age, sex, BMPR2 mutations identified, pre-transplant right heart catheterization data, and PAH 
medication usage of subjects for diseased PASMCs and PAECs. All diseased subjects were clinically diagnosed 
with idiopathic pulmonary arterial hypertension (IPAH). 1Calculated using Fick cardiac output. N/A: data not 
available. 2PDE5inh: PDE5 inhibitor; ERA: Endothelin Receptor Antagonist; Prost.: Prostacyclin Analog. Codes 
for each category (-: none used in that category): PDE5 inhibitor: S: sildenafil, T: tadalafil ERA: B: bosentan, 
A: ambrisentan, M: macitentan Prost.: E: epoprostenol, T: treprostinil (intravenous). 3Mutation judged likely 
pathogenic as it may disrupt mRNA splicing.
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Figure 1. Analysis of 13C-labeled metabolite content derived from [1,2,3-13C3] glucose indicates increased 
glycolysis and pentose shunt flux in diseased PASMCs, and increased proximate glycolysis metabolites with 
decreased pentose shunt flux in diseased PAECs. (a) 13C3-Labeled glycolytic intermediates hexose phosphate 
(HP), fructose bisphosphate (F2P), glyceraldehyde-3-phosphate (G3P), 1,3-bisphosphoglycerate (BPG), 
phosphoglycerate (PG), phosphoenolpyruvate (PEP), pyruvate (Pyr), and lactate (Lac) in the cell pellet 
or supernatant (Sup) of control or diseased PASMCs. (b) 13C2-Labeled glycolytic intermediates (derived 
from pentose shunt metabolism) glyceraldehyde-3-phosphate, 1,3-bisphosphoglycerate, phosphoglycerate, 
phosphoenolpyruvate, and lactate in in control and diseased PASMCs cell pellet or supernatant; no 13C2-
pyruvate was detected. (c) 13C-labeled TCA cycle metabolites citrate (Cit), α-ketoglutarate (αKg), succinate 
(Suc), fumarate (Fum) and malate (Mal); no labeled oxaloacetate was detected. (d) 13C3-Labeled glycolytic 
intermediates hexose phosphate, fructose bisphosphate, glyceraldehyde-3-phosphate, 1,3-bisphosphoglycerate, 
phosphoglycerate, phosphoenolpyruvate, pyruvate, and lactate in the cell pellet or supernatant of control or 
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observed shift to glycolysis in PASMCs previously reported5. We observed an increase in 13C2-labeled lactate in 
the cell pellet similar to that observed with 13C3 lactate (Fig. 1b), suggestive of increased pentose shunt flux in 
diseased PASMCs. We also assessed for the 13C enrichment of TCA cycle metabolites, but found no significant 
differences in the diseased cells (Fig. 1c). Overall, these results indicate IPAH PASMCs have increased glucose 
metabolism through glycolysis and the pentose shunt, but not into the TCA cycle.
Diseased pAecs have increased proximate glycolysis metabolites, with less pentose shunt 
metabolism. In the PAECs, we observed a higher content of the proximate glycolysis metabolites, signifi-
cantly for fructose bisphosphate and a trend for hexose phosphate (P = 0.051; hexose phosphate is the combina-
tion of the isotopomers glucose phosphate and fructose phosphate), but no differences in more distal metabolites 
in the glycolytic pathway such as pyruvate or lactate (Fig. 1d). Also in contrast to the PASMCs, we found a 
reduction in 13C2-lactate in the supernatant indicative of less pentose shunt flux (Fig. 1e). We found no significant 
changes in the incorporation of 13C-labeled carbons into the TCA cycle in IPAH samples (Fig. 1f).
We looked for correlations in the glycolysis phenotype between PAECs and PASMCs in the cells in each group 
derived from the same individual (N = 3/group) by assessing lactate in the supernatant, but did not observe 
any significant correlations (Fig. 1g). We compared cells derived from male versus female PAH subjects, and by 
pre-transplant PAH medication regimen, but found no differences (Supplementary Figs. 1 and 2). We also looked 
for correlations with the severity of disease, as measured by mean pulmonary artery pressure pre-transplant, 
but found no significant correlations (Supplementary Fig. 3). Finally, we assessed BMPR2 mRNA expression by 
RT-PCR in a subset of the samples (not including 1 sample with a BMPR2 mutation), and looked for correlations 
in the glycolysis phenotype with BMPR2 expression: we found suggestive inverse correlations in pyruvate content 
with BMPR2 expression in the cells, but otherwise observed no significant correlations (Supplementary Fig. 4).
pAecs but not pASMcs have increased glutamine-derived anaplerosis. Glutamine is metabo-
lized by cells as an alternative source of carbons to replenish the TCA cycle, a process termed anaplerosis. Using 
Figure 2. Analysis of 13C-labeled metabolite content derived from [13C5,15N2] glutamine indicates increased 
glutamine-derived anaplerosis in diseased PAECs but not PASMCs. (a) 13C and 15N-labeled metabolites 
glutamine (Gln) and glutamate (Glm); citric acid cycle metabolites α-ketoglutarate (αKg), succinate (Suc), 
fumarate (Fum), malate (Mal) and citrate (Cit; no 13C4-oxaloacetate was detected); and glutathione (GSH) in 
the cell pellet from control and diseased PASMCs. (b) 13C and 15N-labeled metabolites glutamine and glutamate; 
citric acid cycle metabolites α-ketoglutarate, succinate, fumarate, malate and citrate (no 13C4-oxaloacetate was 
detected); and glutathione in the cell pellet from control and diseased PAECs. (N = 5 samples per group, from 5 
different control and 5 different disease subjects; unpaired t-test; *P < 0.05; mean ± SEM plotted).
diseased PAECs; no 13C3-glyceraldehyde-3-phosphate or 13C3-phosphoglycerate were detected. (e) 13C2-Labeled 
1,3-bisphosphoglycerate, phosphoenolpyruvate, and lactate in in control and diseased PAECs cell pellet or 
supernatant; no 13C2- glyceraldehyde-3-phosphate, phosphoglycerate, pyruvate or lactate in the pellet was 
detected. (f) 13C-labeled citrate, α-ketoglutarate, succinate, fumarate and malate; no labeled oxaloacetate was 
detected. (N = 5 samples per group, from 5 different control and 5 different disease subjects; unpaired t-test; 
*P < 0.05, **P < 0.01; mean ± SEM plotted.) (g) Scatter plot of M + 3 lactate in the supernatant from PAECs 
and PASMCs obtained from the same individual (N = 3/group).
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[13C5,15N2]glutamine (all 5 carbons and both nitrogens labeled), we found no changes in the incorporation of 
glutamine-derived carbons into the TCA cycle in diseased PASMCs compared to control cells (Fig. 2a). In PAECs, 
we observed the diseased cells had more 13C-labeled succinate, consistent with increased glutamine-derived 
anaplerosis (Fig. 2b).
We also detected 13C5-citrate in the PAECs (Fig. 2b), indicating reductive carboxylation (or retrograde) metab-
olism in the TCA cycle, which has been previously described in endothelial cells15. There was no change in the 
degree of reductive carboxylation in IPAH cells. This species was not detected in the PASMCs.
no evidence of Significantly Altered Long chain fatty Acid Utilization by pASMcs or 
pAecs. We then assessed long chain fatty acid utilization by PASMCs and PAECs. We employed a mixture of 
4 uniformly stable isotope-labeled fatty acids, [13C16]palmitic acid (16:0), [13C16]palmitoleic acid (16:1), [13C18]
oleic acid (18:1) and [13C18]lineoleic acid (18:2). We employed a mixture to avoid bias in possible preferential 
uptake and utilization of specific fatty acids. We assessed the relative content of the four labeled fatty acid sub-
strates remaining in the media of PASMCs and PAECs after 24 hours, and found all four depleted to a comparable 
degree (data not shown).
In PASMCs, we found no differences in the cellular content of the labeled fatty acids between IPAH and con-
trol cells (Fig. 3a). We also found no differences in the content of labeled 13C-labeled two carbon fragments (the 
product of β-oxidation breakdown of labeled fatty acids), or 13C2-citrate resulting from incorporation of the two 
carbon fragments into the TCA cycle in the diseased cells (Fig. 3b).
In PAECs, we similarly found no significant changes in 13C-labeled fatty acid incorporation into the cells 
(Fig. 3c). There was, however, a decrease in 13C enrichment into the TCA cycle at the level of α-ketoglutarate in 
diseased compared to control cells (Fig. 3d), indicating a decrease in utilization of fatty-acid derived carbons in 
the TCA cycle.
Figure 3. Analysis of 13C-labeled metabolite content derived from 13C-labeled long chain fatty acids (LCFAs) 
indicates decreased fatty acid-derived anaplerosis in PAECs but not PASMCs. (a) 13C-Labeled LCFAs in the cell 
pellet from control and diseased PASMCs. (b) 13C2-acyl-C2 and 13C2-labeled citric acid cycle metabolites citrate 
(Cit), succinate (Suc), fumarate (Fum) and malate (Mal); no 13C2-α-ketoglutarate or 13C2-oxaloacetate were 
detected. (c) 13C-Labeled LCFAs in the cell pellet from control and diseased PAECs. (d) 13C2-Labeled citric acid 
cycle metabolites citrate, α-ketoglutarate, succinate, fumarate and malate; no 13C2-acyl-C2 or 13C2-oxaloacetate 
were detected. (N = 5 samples per group, from 5 different control and 5 different disease subjects; unpaired 
t-test; ***P < 0.005; mean ± SEM plotted).
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tGf-β treatment also promotes increased glycolysis in pASMcs. Increased TGF-β signaling is a 
key component of many forms of human and experimental PH. We treated PASMCs and PAECs with TGF-β to 
see if this would phenocopy the disease phenotype in control cells, or augment the phenotype in diseased cells. 
We used 1 ng/mL of activated TGF-β1, a physiologic dose that has been used extensively in both PASMC16,17 and 
PAEC18,19 studies.
Using the [1,2,3-13C3]glucose substrate, we observed increased 13C3 lactate in the supernatant of both control 
and diseased PASMCs treated with TGF-β, compared to respective untreated cells (Fig. 4a,b), indicating that 
TGF-β can phenocopy the glycolytic phenotype. We did not, however, find any significant changes in the pro-
duction of 13C2 lactate, indicating that TGF-β has less impact on pentose shunt flux. In PAECs, we found TGF-β 
treatment had no consistent effects on either 13C3 or 13C2 labeled glycolysis intermediates or lactate (Fig. 4c,d).
Using the [13C5, 15N2]glutamine substrate, we found TGF-β treatment of control PASMCs decreased the 
incorporation of 13C carbons into the TCA cycle, at the level of fumarate and malate (Fig. 5a)–in contrast to the 
absence of a phenotype between diseased and control PASMCs observed above. There was no significant impact 
of TGF-β on diseased PASMCs (Fig. 5b). TGF-β treatment did not appear to have a consistent impact on glu-
tamine uptake or utilization by PAECs, although TGF-β did decrease 13C5-labeled α-ketoglutarate in the diseased 
cells (Fig. 5c,d).
Using the U-13C-labeled LCFA mixture, we observed control PASMCs treated with TGF-β had an increase in 
13C2 incorporation into citrate (Fig. 6a), and diseased PASMCs treated with TGF-β had an increase in the content 
of 13C-labeled 2 carbon fragments in the cells (Fig. 6b)—indicative of increased fatty acid metabolism. In contrast, 
TGF-β treatment of control PAECs phenocopied the disease phenotype, with decreased 13C2-α-ketoglutarate 
(Fig. 6c,d).
Figure 4. Analysis of 13C-labeled metabolite content derived from [1,2,3-13C3]glucose indicates TGF-β 
increases glycolysis in PASMCs. (a,b) 13C3- and 13C2-Labeled lactate (M + 3 lactate is derived from glycolysis 
and M + 2 lactate is derived from pentose shunt metabolism) in the supernatant of (a) control or (b) diseased 
PASMCs, treated with or without TGF-β. (c,d) 13C3- and 13C2-Labeled lactate in the supernatant of (c) control 
or (d) diseased PAECs, treated with or without TGF-β. (N = 5 samples per group, from 5 different control and 5 
different disease subjects; paired t-test; *P < 0.05).
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in tGf-β-treated pASMcs, glucose, glutamine and fatty acids are all carbon sources for the tcA 
cycle. The TCA cycle is the hub for carbons metabolized by cells, both in terms of a destination for substrate 
catabolism and a source for anabolism. DCA is thought to function by increasing glucose flux into the TCA 
cycle, away from lactate5. We thus wondered if the metabolic shift seen in TGF-β-treated PASMCs would cause 
the majority of TCA cycle carbons to be derived from sources other than glucose. To assess this possibility, we 
sought to determine the relative contribution of carbons to TCA cycle intermediates in TGF-β treated PASMCs. 
To do so, we used cultured human PASMCs (Lonza) treated with inhibitors of glucose metabolism, glutamine 
metabolism, or fatty acid metabolism, and then assessed the change in uptake and incorporation of the substrates 
for each pathway. TGF-β treatment of the cultured PASMCs induced similar metabolic shifts compared to TGF-β 
treatment of the control donor PASMCs used above, including increased glycolysis and decreased glutaminolysis 
(data not shown).
We first confirmed that the metabolic inhibitors were effective. We observed that inhibiting hexokinase with 
2-deoxyglucose significantly blocked the downstream metabolism of glucose (Fig. 7a); inhibiting glutaminase 
with CB-839 significantly blocked the downstream metabolism of glutamine (Fig. 7b); and inhibiting fatty acid 
transport into the mitochondria with the carnitine palmitoyltransferase 1 (CPT1) inhibitor oxfenicine signifi-
cantly blocked fatty acid β-oxidation (Fig. 7c).
Figure 5. Analysis of 13C-labeled metabolites derived from [13C5,15N2]glutamine indicates decreased glutamine-
derived anaplerosis in control PASMCs treated with TGF-β. (a,b) 13C-Labeled citric acid cycle metabolites 
α-ketoglutarate (αKg), succinate (Suc), fumarate (Fum), malate (Mal) and citrate (Cit; no 13C4-oxaloacetate 
was detected) in the cell pellet from (a) control or (b) diseased PASMCs, treated with or without TGF-β. (c,d) 
13C-Labeled citric acid cycle metabolites α-ketoglutarate, succinate, fumarate, malate and citrate (no 13C4-
oxaloacetate was detected) in the cell pellet from (c) control or (d) diseased PAECs, treated with or without TGF-
β. (N = 5 samples per group, from 5 different control and 5 different disease subjects; paired t-test; *P < 0.05).
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We then quantified the relative incorporation of labeled substrates into 13C2-citrate with and without inhibi-
tion. We found that there were significant decreases in the incorporation of glucose blocked by 2-deoxyglucose 
and fatty acids blocked by oxfenicine, and a modest trend (P = 0.11) towards less incorporation of glutamine 
after CB-839 treatment (Fig. 7d). We then quantified the total (unlabeled) content of TCA cycle interme-
diates. We found significant decreases in the content of multiple TCA metabolites intermediates with all 
3 treatments–2-deoxyglucose, CB-839, and oxfenicine–with the most significant decreases observed with 
2-deoxyglucose treatment (Fig. 7e). These data indicate that in TGF-β-treated PASMCs–despite metabolic shifts 
including increased glycolysis, decreased glutamine-derived anaplerosis, and increased fatty acid β-oxidation–
glucose, glutamine and fatty acids all contribute carbons to the TCA cycle, although potentially glucose more so 
than the others.
Discussion
Shifts in cellular metabolism have long been recognized as a hallmark of cancer pathobiology20, and are increas-
ingly recognized in PH as well. In both cancer and PH, one of the critical metabolic shifts is increased aerobic 
glycolysis (also known as the Warburg phenomenon), which supports a pro-proliferative, anti-apoptotic pheno-
type1. In addition to increased glucose metabolism to lactate and not to TCA cycle intermediates, the Warburg 
phenomenon also includes aberrant mitochondrial oxygen sensing through epigenetic mechanisms, effectively 
Figure 6. Analysis of 13C-labeled metabolites derived from 13C-labeled long chain fatty acids (LCFAs) indicates 
TGF-β increases the incorporation of fatty acid-derived carbons into the TCA cycle in PASMCs but decreases 
it in PAECs. (a,b) 13C2-acyl-C2 (a2:0) and 13C2-labeled citric acid cycle metabolites citrate (Cit), succinate 
(Suc), fumarate (Fum) and malate (Mal; no 13C2-α-ketoglutarate or 13C2-oxaloacetate were detected) in the 
cell pellet from (a) control or (b) diseased PASMCs, treated with or without TGF-β. (c,d) 13C-Labeled citric 
acid cycle metabolites citrate, α-ketoglutarate (αKg), succinate, fumarate, and malate (no 13C2-acyl-C2 or 13C2-
oxaloacetate was detected) in the cell pellet from (c) control or (d) diseased PAECs, treated with or without 
TGF-β. (N = 5 samples per group, from 5 different control and 5 different disease subjects; paired t-test; 
*P < 0.05).
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resulting in “a state of pseudohypoxia” which contributes to PH pathogenesis21. Molecularly, hypoxia-inducible 
factor-1α is a master regulator of glycolysis, and is increased in both PH and cancer22–24.
Compared to glycolysis, pentose shunt metabolism has been less studied in PH. The enzyme which regulates 
glucose-6-phosphate entry into the pentose shunt, glucose-6-phosphate dehydrogenase, has been observed to 
be increased in hypoxic PASMCs25. One function of the pentose pathway is the generation of cytosolic NADPH, 
which can be used to reduce oxidized glutathione (GSSG) and regenerate active site thiols in antioxidant enzymes 
in settings of oxidative stress which may be present in PH.
Figure 7. The TCA cycle of TGF-β-treated PASMCs derives carbons from glucose, glutamine and fatty acids. 
(a) Effect of the hexokinase inhibitor 2-deoxyglucose (2-DG) on 13C3-labeled glycolysis intermediates hexose 
phosphate (HP), fructose bisphosphate (F2P), glyceraldehyde-3-phosphate (G3P), phosphoglycerate (PG), 
phosphoenolpyruvate (PEP), and lactate (Lac) derived from [1,2,3-13C3]glucose in the cell pellet; no labeled 
13C3-1,3-bisphosphoglycerate or 13C3-pyruvate were detected. (b) Effect of the transglutaminase inhibitor CB-
839 on 13C5,15N-glutamate (Glm) and 13C5-α-ketoglutarate (αKg) derived from [13C5,15N2]glutamine. (c) Effect 
of the carnitine palmitoyltransferase 1 inhibitor oxfenicine (Oxf) on intracellular fatty acid metabolites derived 
from 13C-labeled fatty acids. (d) Effect of 2-deoxyglucose, CB-839 and oxfenicine on the contribution of 13C2 to 
citrate deriving from 13C-labeled glucose, glutamine and fatty acids, respectively. (e) Effect of 2-deoxyglucose, 
CB-839 and oxfenicine on the total content of the TCA metabolites citrate (Cit), α-ketoglutarate (αKg), 
succinate (Suc), fumarate (Fum), malate (Mal) and oxaloacetate (Oxa). (A-D: N = 3 samples per group, E: 
N = 3 samples per group, with 3 replicates, pooled; unpaired t-test between samples; *P < 0.05, **P < 0.01, 
***P < 0.005, ****P < 0.001; mean ± SEM plotted).
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Altered TGF-β family signaling underlies many forms of pulmonary hypertension (PH), as evidenced by 
mutations in TGF-β pathway members underlying heritable PH; increased TGF-β signaling present in human 
and animal PH model lung tissue; and excessive activation of latent TGF-β26. Blockade of TGF-β signaling is 
protective in multiple forms of experimental PH13,27–29, and clinical trials targeting TGF-β family ligands and 
receptors are currently ongoing. However, mechanisms by which aberrant TGF-β signaling results in the vascular 
pathology have not been fully elucidated. Knockdown of BMPR2 has shown to promote glycolysis30; here in small 
numbers of samples we did not observe consistent trends between BMPR2 expression and glycolysis parameters. 
We did find evidence that TGF-β treatment can promote and augment a shift to glycolysis in PASMCs. These 
results are consistent with data that TGF-β can increase glucose utilization by fibroblasts31, although TGF-β did 
not phenocopy all aspects of the metabolic phenotype in IPAH cells.
We used stable isotope metabolic tracing in vitro in conjunction with mass spectrometry-based metabolo-
mics to evaluate the uptake and utilization of three key metabolic substrates: glucose, glutamine and fatty acids. 
13Carbon and 15N are non-radioactive and do not decay, and thus can be used for the tracing of labeled atoms 
into downstream metabolites32. Enzymes have a mild substrate preference for molecules containing lighter iso-
topes, which may induce bias in 13C-tracking studies, but in general these effects are thought to be very minor33. 
Substrates other than glucose, glutamine and fatty acids may serve as alternative carbon and energy sources in 
mammalian cells, but these three compounds account for the majority of substrates. In the context of pathology, 
cells shift how carbon atoms flow through the cells: for example, in cancer cells the shift in glucose utilization to 
glycolysis from glucose oxidation is accompanied by increased glutaminolysis to fuel the TCA cycle34. All three 
substrates have the potential to contribute carbon atoms to the TCA cycle, as we observed with PASMCs here.
Stable isotope metabolomics complements steady state metabolomics, which assesses the content of unlabeled 
metabolites in cells. Fessel et al. used steady-state metabolomics to study human PAECs transfected with mutant 
bone morphogenetic protein receptor 2 (BMPR2), a TGF-β receptor family member and a common driver of 
heritable human PH35. The authors found an increase in proximate glycolytic pathway intermediates, which 
corresponds well with our data finding an increase in proximate 13C-labeled glycolytic pathway intermediates 
derived from 13C-labeled glucose. They also observed a decrease in fatty acid β-oxidation intermediates, which 
corresponds to the decrease in 13C-labeled α-ketoglutarate derived from 13C-fatty acid catabolism we observed. 
Finally, they also reported a decrease in glutamine-derived metabolites; here, our results diverge as we found 
evidence of increased labeled succinate derived from glutamine.
Endothelial cell proliferation has been reported to require all three of glycolysis, fatty acid β-oxidation and 
glutamine metabolism. In endothelial cells, glycolytic flux is mediated by upregulation of PFKFB3, and blockade 
of PFKFB3 can suppress angiogenesis36. Fatty acid metabolism is also required for angiogenesis, but here the 
carbons are used for de novo nucleotide synthesis to support DNA replication37. Blocking glutamine metabolism 
induces endothelial cell senescence38; as observed by ourselves and others15, glutamine-derived α-ketoglutarate 
can undergo reductive carboxylation, likely to support the fatty acid and phospholipid anabolism required to 
maintain membrane homeostasis in these cells with a very high ratio of surface area to volume39. The requirement 
for membrane synthesis is PAECs also supported by our observation that 13C labeled carbons may leave glycolysis 
at an intermediate step: glycerol is produced from glyceraldehyde 3-phosphate, and is also a critical component 
of phospholipids.
In PH, diseased PAECs have a decrease in oxygen consumption (corresponding to a decrease in mitochon-
drial respiration), and the density of mitochondria per cell is decreased in IPAH-derived PAECs compared to 
control PAECs6. Increased stiffness of the underlying matrix is sufficient to induce increased glycolysis and YAP/
TAZ-dependent glutaminolysis in PAECs, a metabolic shift which supports proliferation of the cells10, and which 
we also found evidence for here in IPAH-derived cells. Endothelial-to-mesenchymal transition (EndoMT) of 
ECs, induced in vitro by a combination of TGF-β and IL-1β, causes a decrease in fatty acid β-oxidation, while 
suppressing fatty acid β-oxidation (as we observed occurred in the PAECs treated with TGF-β) is sufficient to 
induce EndoMT40.
To analyze fatty acid metabolism here we used a stable isotope-labeled mixture of palmitic acid, palmitoleic 
acid, oleic acid and lineolic acid to assess uptake and utilization in PASMCs and PAECs. This approach has the 
disadvantage of not allowing the discrete analysis of specific fatty acid substrates, which could be handled differ-
ently. However, the relevance of the substrates we analyzed is supported by the reported increase in circulating 
plasma concentrations of palmitic acid, oleic acid and lineolic acid by 12.0, 5.0 and 4.9-fold, respectively, in PAH 
versus control subjects41.
The pathologic phenotype of PH cells can be reversed, at least in part, by targeting the altered metabolism. 
Excessive proliferation and apoptosis resistance in PASMCs can be reversed by increasing glucose oxidation by 
treating the cells with DCA or blocking fatty acid oxidation such as with ranolazine, which increases glucose 
intake into the cells via the Randle cycle5,41,42. Our studies broaden these data, with the observation that even in 
the context of increased glycolysis induced by TGF-β in PASMCs, glucose remains a major source of carbons for 
the TCA cycle.
The possibility of targeting the PH pathology by modulating metabolism has led to clinical trials using DCA 
as a pharmacologic treatment for PAH, which has shown promise particularly in individuals who lack genetic 
mutations in other pathways9. If pharmacologic TGF-β modulation has clinical benefit, such as by the ligand 
trap soterdacept, it is likely that a beneficial mechanism will be through modulating cellular metabolism. By 
targeting similar pathways, metabolic treatments may be found to have a synergistic effect with TGF-β pathway 
modulators.
An important limitation on making comparisons between PASMCs and PAECs in our study is the use of 
different cell culture media specific for smooth muscle and endothelial cells, which likely impacts the metabolic 
phenotype of the cells. For example, the smooth muscle cell media we used contains 2% fetal bovine serum (FBS) 
whereas the endothelial cell media contains 5% FBS: FBS contains hormones and other growth factors such as 
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insulin and cortisol that impact metabolism. Another limitation on comparing the relative uptake between differ-
ent labeled metabolites is that the stable isotope-labeled metabolites were added to the media, adding to unlabeled 
metabolites already present. For example, the addition of [1,2,3-13C3]glucose increased the total glucose concen-
tration in the media, which may itself increase glucose uptake by cells42. We also have not, here, directly identi-
fied which metabolic pathways contribute to specific pathologic phenotypes in each cell type. Other limitations 
include the relatively small sample size, as primary cell lines obtained from cultured organs are a precious and 
scarce resource, and related to this we used cells at relatively high passage numbers because of the large number 
of experiments and numbers of cells required to generate high fidelity results.
In summary, we found evidence of a metabolic shift in diseased PASMCs, including increased glycolysis and 
pentose shunt flux. In PAECs, we found more modest changes, including an increase in several proximate inter-
mediates in glycolysis, less pentose shunt flux, and increased glutamine-derived anaplerosis with less fatty acid 
fueling of the TCA cycle. These data suggest that therapeutic strategies addressing the altered cellular metabolism 
in PH may be most effective if they target specific cell compartments.
Methods
cells and culture techniques. Primary PASMCs and PAECs. Primary PASMCs and PAECs were 
obtained from the cell studies core of the Pulmonary Hypertension Breakthrough Initiative (PHBI) Research 
Network (Philadelphia, PA). The PASMCs were cultured in Smooth Muscle Cell Medium (SMCM; ScienCell 
Research Laboratories, Carlsbad, CA; Cat#1101). The PAECs were cultured in Vasculife EC complete kit (Lifeline 
Cell Technology, Frederick, MD; Cat#LL-0005). Both the PASMC and PAEC media contain 5.5 mM glucose and 
10 mM glutamine. Both PASMCs and PAECs were cultured at 37 °C with an atmosphere of 5% CO2 (95% air) and 
100% humidity. The cells were grown to no more than 90% confluence, and sub-cultured at a density of a least 
5.0 × 105 cells in 100 mm diameter dishes. Both primary cell types were used between passages 7 and 9. Viability 
was determined using trypan blue exclusion dye by light microscopy.
Cultured PASMCs. For the metabolic inhibitor experiments, we used cultured PASMCs from Lonza 
(Walkersville, MD; Cat#CC-2581). The cells were cultured as described above in SMCM.
Sample collection. PASMCs and PAECs from 5 controls (Failed Donors) and 5 diseased subjects (idiopathic pul-
monary arterial hypertension; IPAH; see Table 1) were cultured in their respective culture media to 85–90% con-
fluence, adding fresh media every 2–3 days (the rate of growth varied depending on cell type). When the cultures 
reached target confluence, the cells were treated under different conditions for 24 hours, at 37 °C with an atmos-
phere of 5% CO2 (95% air) and 100% humidity. After 24 hours treatment, the cells were harvested; collecting 1 ml 
of supernatant media which was snap frozen in liquid nitrogen. The rest of the media was removed from the plate 
and the cells were washed twice with sterile PBS and trypsinized for 2–5 min at 37 °C. 3 ml of the respective cold 
media was added and the plate washed with 2 ml of cold ice PBS. The cells were pooled in 15 ml conical tubes and 
centrifuged 5 min at 1000 rpm at room temperature. The recovered pellet was then resuspended into 1 ml of ice 
cold PBS, and an aliquot counted via heamocytometer. The cell suspension was centrifuged 3 min at 1600rpm at 
4 °C and the final pellet snap frozen in liquid N2. Media supernatants and cell pellets were stored at −70 °C until 
mass spectrometry analysis. Experiments using cultured PASMCs were performed in the same manner.
BMPR2 quantification. mRNA was isolated from PASMCs and PAECs, and RT-PCR used to quantify expression 
of BMPR2 and β-actin using the 2−ΔCt method.
treatments, including labeled metabolic substrates. Primary PASMCs and PAECs were treated with 
or without 1 ng/ml human recombinant human TGF-β1 (Invitrogen, Carlsbad, CA; Cat# 14-8348-62) at the same 
time as metabolic substrates were added to the respective culture media for the same duration of time, 24 hours. 
The metabolic substrates were 1 mg/ml of [1,2,3-13C3]glucose (Sigma-Aldrich, St. Louis, MO, Cat#720127); 4 mM 
[13C5;15N2]glutamine (Cambridge Isotope Laboratories Inc., Tewksbury, MA; Cat# CNLM-1275-H); and 100 µM 
13CU-mixed fatty acids (Cambridge Isotope Laboratories Inc.; Cat# CLM-8455-1).
Cultured PASMCs were used for inhibition experiments using the same protocols as above, with the fur-
ther addition of metabolic inhibitors, with 10 µM CB-839 (Sellechem, Houston TX; Cat# S7655); 1 mM 
4-hydroxy-L-phenylglycine (oxfencine; Sigma-Aldrich; Cat# 56160); or 2 mg/ml 2-deoxy-D-glucose 
(Sigma-Aldrich; Cat# D8375).
Metabolomics assessment. Frozen cell pellets were extracted at 2 × 106 cells/mL in ice cold lysis/extrac-
tion buffer (methanol:acetonitrile:water 5:3:2, v/v/v). Twenty µL of supernatant samples was extracted with 480 µL 
of extraction buffer. Samples were agitated at 4 °C for 30 min followed by centrifugation at 10,000 g for 10 min 
at 4 °C. Protein and lipid pellets were discarded, and extracts were injected (10 µL for cell samples; 20 µL for 
supernatant samples) into a UHPLC system (Vanquish, Thermo, San Jose, CA, USA) and run on a Kinetex C18 
column (150 × 2.1 mm, 1.7 µm – Phenomenex, Torrance, CA, USA). Solvents were Optima H2O (Phase A) and 
Optima acetonitrile (Phase B) supplemented with 0.1% formic acid for positive mode runs and 1 mM NH4OAc 
for negative mode runs. Samples were analyzed using a 9 min gradient from 5–95% organic phase at 400 µL/
min43. The autosampler was held at 7 °C for all runs; the column compartment was held at 45 °C. The UHPLC 
system was coupled online with a Q Exactive mass spectrometer (Thermo, Bremen, Germany), scanning in Full 
MS mode (2 µscans) at 70,000 resolution in the 60–900 m/z range in negative and then positive ion mode (sep-
arate runs). Eluate was subjected to electrospray ionization (ESI) with 4 kV spray voltage. Nitrogen gas settings 
were 45 sheath gas and 15 auxiliary gas. Metabolite assignments and isotopologue distributions were determined 
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using Maven (Princeton, NJ, USA), following conversion of.raw files to.mzXML format through RawConverter. 
Chromatographic and MS technical stability were assessed by determining CVs for heavy and light isotopologues 
in a technical mixture of extract run every 10 injections.
Statistics. Relative quantitation was performed by exporting the values for integrated peak areas of light 
metabolites and their isotopologues into Excel (Microsoft, Redmond, CA, USA) for statistical analysis including 
t-test and ANOVA (significance threshold for p-values < 0.05). Data was plotted using GraphPad Prism (La Jolla, 
CA, USA). P < 0.05 was considered statistically significant.
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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